


-222-

We claim:

1. A compound of Formula I



wherein:

R<sup>1</sup> is C<sub>6</sub>H<sub>5</sub>CH<sub>2</sub>OCH<sub>2</sub>-, C<sub>6</sub>H<sub>5</sub>(CH<sub>2</sub>)<sub>3</sub>- or indol-3-ylmethyl;

Y is pyrrolidinyl, 4-methyl piperidinyl or NR<sub>2</sub>R<sub>2</sub>;

R<sub>2</sub> are each independently a C<sub>1</sub> to C<sub>6</sub> alkyl;

R<sub>3</sub> is 2-naphthyl or phenyl para-substituted by W;

W is H, F, CF<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkoxy or phenyl; and

R<sub>4</sub> is H or CH<sub>3</sub>,

or a pharmaceutically salt or solvate thereof.

2. A compound of Claim 1 wherein R<sup>4</sup> is CH<sub>3</sub>.
3. A compound of Claim 1 wherein said compound has the (R,R) stereo configuration.
4. A method for increasing the level of endogenous growth hormone in a human or an animal which comprises administering to said human or animal an effective amount of a compound of Claim 1.
5. A method for the treatment or prevention of a physiological condition which may be modulated by an increase in endogenous growth hormone which comprises

-223-

administering to an animal in need of said treatment an effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt or solvate thereof.

- 5 6. A pharmaceutical formulation which comprises, as an active ingredient a compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, associated with one or more pharmaceutically acceptable carriers, diluents, or excipients.
- 10 7. A pharmaceutical formulation according to Claim 6 which further comprises a bone-antiresorptive agent.
- 15 8. A method according to Claim 7 which further comprises administering to a patient a bone antiresorptive agent.
9. A method according to Claim 8 wherein said bone antiresorptive agent is a bisphosphonate.

00000163-072501  
1052/0" 09T0900